Enlivex
ENLV2.20048.36% ( -2.060 )
Enlivex (ENLV)
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a ce...
- Open
- 3.260
- High
- 3.260
- Low
- 2.160
- Prev. Close
- 4.260
- Volume
- 3.85M
- Turnover
- 12.85M
- Avg Price
- 3.340
- Bid/Ask Ratio
- --
- Amplitude
- 25.82%
- 52wk High
- 31.500
- Volume Ratio
- 49.42
- Turnover Ratio
- 82.43%
Enlivex Analyst Rating
View MoreForecast & Rating
Apr 23, 2026Price forecast
$300.0013536.36%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · 2 hours ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga_article · 3 hours ago
Crude Oil Down Over 5%; Boeing Shares Rise After Q2 Results
- PUBT · 7 hours ago
Enlivex prices USD 400 million private placement at USD 5 per share
- Market Beat · Jul 24 at 10:20 PM
Short Interest in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Declines By 98.2%
- PUBT · Jul 20 at 07:05 AM
Enlivex says July 18 NAV per share is USD 66.16
- PUBT · Jul 13 at 07:04 AM
Enlivex notifies availability of press release on FDA RMAT designation for Allocetra in knee osteoarthritis
